Towards bedside gene therapies: Development of a microfluidic gene delivery device for immune cell modificiation and optimisation for clinical use

Banner Image

Pictured: Indee Labs CEO Warren McKenzie, MTPConnect Chair Sue MacLeman, MTAA CEO Ian Burgess and ANFF-SA National Facility Manager Simon Doe at the launch of the BioMedTech Horizons in April 2018 in Melbourne.

Wealthy terminally ill patients can now access pioneering cures to their conditions, including many forms of cancer, thanks to a new generation of treatments called gene-modified cell therapies (GMCTs). Kymriah and Yescarta were the first to be approved by the United States Food and Drug Administration last year and there are many hundreds more in development.

Indee Labs plans to make GMCTs accessible to the masses by solving the manufacturing issues responsible for their high price tags. It will also reduce the lead times for a treatment from months to weeks saving the lives of patients with aggressive conditions.

Gene delivery to cells is the most critical and problematic step in manufacturing GMCTs. Our project will develop the only practical gene delivery technology, microfluidic vortex shedding (µVS), into a product that will be trialled by pharmaceutical companies. µVS will offer revolutionary improvements over existing gene delivery methods including high yield, negligible immune cell perturbation along with rapid processing of research-, clinical- and commercial-scale samples with a simple workflow and a small footprint.

Visit Indee Labs to learn more.

Case Studies:

Twitter: @indeelabs

LinkedIn: indee labs

Consortium LeadIndee Pty Ltd
Consortium PartnersUniversity of South Australia Future Industries Institute, Main Sequence Ventures, Defence Science Technologies Group, University of Sydney & Becton Dickinson
ContactWarren McKenzie, CEO - warren@indeelabs.com